HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2020-08-13

AUTHORS

Doug Coyle, Isabelle Durand-Zaleski, Jasmine Farrington, Louis Garrison, Johann-Matthias Graf von der Schulenburg, Wolfgang Greiner, Louise Longworth, Aurélie Meunier, Anne-Sophie Moutié, Stephen Palmer, Zack Pemberton-Whiteley, Mark Ratcliffe, Jie Shen, Doug Sproule, Kun Zhao, Koonal Shah

ABSTRACT

This last decade has been marked by significant advances in the development of cell and gene (C&G) therapies, such as gene targeting or stem cell-based therapies. C&G therapies offer transformative benefits to patients but present a challenge to current health technology decision-making systems because they are typically reviewed when clinical efficacy data are very limited and when there is uncertainty about the long-term durability of outcomes. These challenges are not unique to C&G therapies, but they face more of these barriers, reflecting the need for adapting existing value assessment frameworks. Still, C&G therapies have the potential to be cost-effective even at very high price points. The impact on healthcare budgets will depend on the success rate of pipeline assets and on the extent to which C&G therapies will expand to wider pathologies beyond rare or ultra-rare diseases. Getting pricing and reimbursement models right is important for incentivising research and development investment while not jeopardising the sustainability of healthcare systems. Payers and manufacturers therefore need to acknowledge each other’s constraints—limitations in the evidence generation on the manufacturer side, budget considerations on the payer side—and embrace innovative thinking and approaches to ensure timely delivery of therapies to patients. Several experts in health technology assessment and clinical experts have worked together to produce this publication and identify methodological and policy options to improve the assessment of C&G therapies, and make it happen better, faster and sustainably in the coming years. More... »

PAGES

1421-1437

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10198-020-01212-w

DOI

http://dx.doi.org/10.1007/s10198-020-01212-w

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1130093751

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32794011


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell- and Tissue-Based Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Policy Making", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rare Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Technology Assessment, Biomedical", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Ottawa, Ottawa, Canada", 
          "id": "http://www.grid.ac/institutes/grid.28046.38", 
          "name": [
            "University of Ottawa, Ottawa, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coyle", 
        "givenName": "Doug", 
        "id": "sg:person.016420255222.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016420255222.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Paris Est, Champs-Sur-Marne, France", 
          "id": "http://www.grid.ac/institutes/grid.466400.0", 
          "name": [
            "University of Paris Est, Champs-Sur-Marne, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Durand-Zaleski", 
        "givenName": "Isabelle", 
        "id": "sg:person.01327533357.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PHMR Ltd, London, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PHMR Ltd, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Farrington", 
        "givenName": "Jasmine", 
        "id": "sg:person.015236747123.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015236747123.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington, Seattle, USA", 
          "id": "http://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "University of Washington, Seattle, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garrison", 
        "givenName": "Louis", 
        "id": "sg:person.01002053374.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002053374.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Health Economics Research, Hannover, Hannover, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Center for Health Economics Research, Hannover, Hannover, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Graf von der Schulenburg", 
        "givenName": "Johann-Matthias", 
        "id": "sg:person.01331377620.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331377620.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bielefeld University, Bielefeld, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7491.b", 
          "name": [
            "Bielefeld University, Bielefeld, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Greiner", 
        "givenName": "Wolfgang", 
        "id": "sg:person.01331127566.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331127566.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bielefeld University, Bielefeld, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7491.b", 
          "name": [
            "Bielefeld University, Bielefeld, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Longworth", 
        "givenName": "Louise", 
        "id": "sg:person.0752636034.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752636034.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PHMR Ltd, London, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PHMR Ltd, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meunier", 
        "givenName": "Aur\u00e9lie", 
        "id": "sg:person.014332745303.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014332745303.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PHMR Ltd, London, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PHMR Ltd, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mouti\u00e9", 
        "givenName": "Anne-Sophie", 
        "id": "sg:person.013455465123.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013455465123.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Health Economics, University of York, York, UK", 
          "id": "http://www.grid.ac/institutes/grid.5685.e", 
          "name": [
            "Center for Health Economics, University of York, York, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palmer", 
        "givenName": "Stephen", 
        "id": "sg:person.012711633277.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012711633277.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Acute Leukemia Advocates Network (ALAN)-Chair, Bern, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Acute Leukemia Advocates Network (ALAN)-Chair, Bern, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pemberton-Whiteley", 
        "givenName": "Zack", 
        "id": "sg:person.07353705215.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07353705215.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PHMR Ltd, London, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PHMR Ltd, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ratcliffe", 
        "givenName": "Mark", 
        "id": "sg:person.011116672503.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011116672503.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shen", 
        "givenName": "Jie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AveXis, Chicago, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "AveXis, Chicago, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sproule", 
        "givenName": "Doug", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "China National Health Development Research Center, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.433167.4", 
          "name": [
            "China National Health Development Research Center, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhao", 
        "givenName": "Kun", 
        "id": "sg:person.01322615152.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322615152.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PHMR Ltd, London, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PHMR Ltd, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shah", 
        "givenName": "Koonal", 
        "id": "sg:person.01172341334.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172341334.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10198-018-1007-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107079490", 
          "https://doi.org/10.1007/s10198-018-1007-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12955-019-1189-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117679632", 
          "https://doi.org/10.1186/s12955-019-1189-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-08-13", 
    "datePublishedReg": "2020-08-13", 
    "description": "This last decade has been marked by significant advances in the development of cell and gene (C&G) therapies, such as gene targeting or stem cell-based therapies. C&G therapies offer transformative benefits to patients but present a challenge to current health technology decision-making systems because they are typically reviewed when clinical efficacy data are very limited and when there is uncertainty about the long-term durability of outcomes. These challenges are not unique to C&G therapies, but they face more of these barriers, reflecting the need for adapting existing value assessment frameworks. Still, C&G therapies have the potential to be cost-effective even at very high price points. The impact on healthcare budgets will depend on the success rate of pipeline assets and on the extent to which C&G therapies will expand to wider pathologies beyond rare or ultra-rare diseases. Getting pricing and reimbursement models right is important for incentivising research and development investment while not jeopardising the sustainability of healthcare systems. Payers and manufacturers therefore need to acknowledge each other\u2019s constraints\u2014limitations in the evidence generation on the manufacturer side, budget considerations on the payer side\u2014and embrace innovative thinking and approaches to ensure timely delivery of therapies to patients. Several experts in health technology assessment and clinical experts have worked together to produce this publication and identify methodological and policy options to improve the assessment of C&G therapies, and make it happen better, faster and sustainably in the coming years.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10198-020-01212-w", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1297512", 
        "issn": [
          "1439-3972", 
          "1439-6637"
        ], 
        "name": "The European Journal of Health Economics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "clinical efficacy data", 
      "ultra-rare disease", 
      "gene therapy", 
      "health technology assessment", 
      "cell-based therapies", 
      "efficacy data", 
      "therapy", 
      "healthcare budgets", 
      "clinical experts", 
      "success rate", 
      "reimbursement models", 
      "healthcare system", 
      "patients", 
      "evidence generation", 
      "development of cells", 
      "wider pathology", 
      "technology assessment", 
      "cells", 
      "HTA methodology", 
      "significant advances", 
      "disease", 
      "gene targeting", 
      "pathology", 
      "long-term durability", 
      "assessment", 
      "outcomes", 
      "payers", 
      "payer side", 
      "delivery", 
      "targeting", 
      "options", 
      "years", 
      "last decade", 
      "timely delivery", 
      "evaluation", 
      "benefits", 
      "rate", 
      "side", 
      "experts", 
      "barriers", 
      "challenges", 
      "advances", 
      "need", 
      "value assessment framework", 
      "extent", 
      "data", 
      "publications", 
      "development", 
      "potential", 
      "impact", 
      "decades", 
      "transformative benefits", 
      "system", 
      "consideration", 
      "research", 
      "point", 
      "model", 
      "manufacturers", 
      "making", 
      "generation", 
      "policy options", 
      "policy making", 
      "assessment framework", 
      "value framework", 
      "durability", 
      "methodology", 
      "price points", 
      "thinking", 
      "uncertainty", 
      "framework", 
      "innovative thinking", 
      "budget considerations", 
      "decision-making system", 
      "budget", 
      "sustainability", 
      "investment", 
      "higher price points", 
      "assets", 
      "development investment", 
      "manufacturer side", 
      "pricing", 
      "pipeline assets"
    ], 
    "name": "HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies", 
    "pagination": "1421-1437", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1130093751"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10198-020-01212-w"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32794011"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10198-020-01212-w", 
      "https://app.dimensions.ai/details/publication/pub.1130093751"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_835.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10198-020-01212-w"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10198-020-01212-w'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10198-020-01212-w'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10198-020-01212-w'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10198-020-01212-w'


 

This table displays all metadata directly associated to this object as RDF triples.

317 TRIPLES      21 PREDICATES      118 URIs      106 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10198-020-01212-w schema:about N03b41c8e4e014b8aa3df933964e1eccb
2 N2855d5acc5c0447bb8f45f67b2c45f5e
3 N65460c8eaf5649b6a6f0edb96832ba32
4 N750c970057074218abfb85e27271e1d2
5 N849ed8d8180f4377bfeca488180057c6
6 N9439207d7b394cc08b4b3a7df588b097
7 Ne5b5e63ea41748c1bf8c842abdf76cad
8 anzsrc-for:11
9 anzsrc-for:1117
10 anzsrc-for:14
11 anzsrc-for:1402
12 schema:author Naf6e6c4232c743ccb84927589f43fc6a
13 schema:citation sg:pub.10.1007/s10198-018-1007-x
14 sg:pub.10.1186/s12955-019-1189-7
15 schema:datePublished 2020-08-13
16 schema:datePublishedReg 2020-08-13
17 schema:description This last decade has been marked by significant advances in the development of cell and gene (C&G) therapies, such as gene targeting or stem cell-based therapies. C&G therapies offer transformative benefits to patients but present a challenge to current health technology decision-making systems because they are typically reviewed when clinical efficacy data are very limited and when there is uncertainty about the long-term durability of outcomes. These challenges are not unique to C&G therapies, but they face more of these barriers, reflecting the need for adapting existing value assessment frameworks. Still, C&G therapies have the potential to be cost-effective even at very high price points. The impact on healthcare budgets will depend on the success rate of pipeline assets and on the extent to which C&G therapies will expand to wider pathologies beyond rare or ultra-rare diseases. Getting pricing and reimbursement models right is important for incentivising research and development investment while not jeopardising the sustainability of healthcare systems. Payers and manufacturers therefore need to acknowledge each other’s constraints—limitations in the evidence generation on the manufacturer side, budget considerations on the payer side—and embrace innovative thinking and approaches to ensure timely delivery of therapies to patients. Several experts in health technology assessment and clinical experts have worked together to produce this publication and identify methodological and policy options to improve the assessment of C&G therapies, and make it happen better, faster and sustainably in the coming years.
18 schema:genre article
19 schema:isAccessibleForFree false
20 schema:isPartOf N9e71587a231d4496bc9b8102b29b6464
21 Nf8137b66c55d421a8769de6136bbc80b
22 sg:journal.1297512
23 schema:keywords HTA methodology
24 advances
25 assessment
26 assessment framework
27 assets
28 barriers
29 benefits
30 budget
31 budget considerations
32 cell-based therapies
33 cells
34 challenges
35 clinical efficacy data
36 clinical experts
37 consideration
38 data
39 decades
40 decision-making system
41 delivery
42 development
43 development investment
44 development of cells
45 disease
46 durability
47 efficacy data
48 evaluation
49 evidence generation
50 experts
51 extent
52 framework
53 gene targeting
54 gene therapy
55 generation
56 health technology assessment
57 healthcare budgets
58 healthcare system
59 higher price points
60 impact
61 innovative thinking
62 investment
63 last decade
64 long-term durability
65 making
66 manufacturer side
67 manufacturers
68 methodology
69 model
70 need
71 options
72 outcomes
73 pathology
74 patients
75 payer side
76 payers
77 pipeline assets
78 point
79 policy making
80 policy options
81 potential
82 price points
83 pricing
84 publications
85 rate
86 reimbursement models
87 research
88 side
89 significant advances
90 success rate
91 sustainability
92 system
93 targeting
94 technology assessment
95 therapy
96 thinking
97 timely delivery
98 transformative benefits
99 ultra-rare disease
100 uncertainty
101 value assessment framework
102 value framework
103 wider pathology
104 years
105 schema:name HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies
106 schema:pagination 1421-1437
107 schema:productId N4fb90492a08a495fbc59bfdbc4a5b0ec
108 Nb99cf922424c49c3a2ee17ab1d16fb16
109 Nf4990d67612f4e3aa22a0e4cacb866c3
110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1130093751
111 https://doi.org/10.1007/s10198-020-01212-w
112 schema:sdDatePublished 2022-09-02T16:04
113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
114 schema:sdPublisher N204f5058765d46818685fedf8ab4331e
115 schema:url https://doi.org/10.1007/s10198-020-01212-w
116 sgo:license sg:explorer/license/
117 sgo:sdDataset articles
118 rdf:type schema:ScholarlyArticle
119 N02082fc11874458989f75098a79d902b rdf:first sg:person.011116672503.34
120 rdf:rest N2418c36f16e843958b6cba7c5b3cb044
121 N02e66c6274f44e24a1c36a8b6fefdcaa schema:affiliation grid-institutes:None
122 schema:familyName Sproule
123 schema:givenName Doug
124 rdf:type schema:Person
125 N03b41c8e4e014b8aa3df933964e1eccb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Technology Assessment, Biomedical
127 rdf:type schema:DefinedTerm
128 N155f00c5e379444494dbf45e8a4d3c00 rdf:first sg:person.015236747123.69
129 rdf:rest Ned39f0b672694d30a9b4d4611ec580f2
130 N204f5058765d46818685fedf8ab4331e schema:name Springer Nature - SN SciGraph project
131 rdf:type schema:Organization
132 N2418c36f16e843958b6cba7c5b3cb044 rdf:first N47bf605659a3498daa1e3184f1108f50
133 rdf:rest N8589d1986dce4a7ab55882af3170a94c
134 N2855d5acc5c0447bb8f45f67b2c45f5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Genetic Therapy
136 rdf:type schema:DefinedTerm
137 N47bf605659a3498daa1e3184f1108f50 schema:affiliation grid-institutes:grid.419481.1
138 schema:familyName Shen
139 schema:givenName Jie
140 rdf:type schema:Person
141 N4fb90492a08a495fbc59bfdbc4a5b0ec schema:name doi
142 schema:value 10.1007/s10198-020-01212-w
143 rdf:type schema:PropertyValue
144 N554d74c43f0c43e594cd05e86a6f2476 rdf:first sg:person.01172341334.33
145 rdf:rest rdf:nil
146 N65460c8eaf5649b6a6f0edb96832ba32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Cost-Benefit Analysis
148 rdf:type schema:DefinedTerm
149 N6d96f2a893c54300b87eb0b1fe98f400 rdf:first sg:person.012711633277.14
150 rdf:rest N756f8d4b3ad24f8694bf7ae146dd22e6
151 N6e6976b1fc524530878d1441f15a08f3 rdf:first sg:person.013455465123.21
152 rdf:rest N6d96f2a893c54300b87eb0b1fe98f400
153 N750c970057074218abfb85e27271e1d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Cell- and Tissue-Based Therapy
155 rdf:type schema:DefinedTerm
156 N756f8d4b3ad24f8694bf7ae146dd22e6 rdf:first sg:person.07353705215.15
157 rdf:rest N02082fc11874458989f75098a79d902b
158 N83d610a1e38e435aa3b6f8f63b2a4c63 rdf:first sg:person.01322615152.98
159 rdf:rest N554d74c43f0c43e594cd05e86a6f2476
160 N849ed8d8180f4377bfeca488180057c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Rare Diseases
162 rdf:type schema:DefinedTerm
163 N8589d1986dce4a7ab55882af3170a94c rdf:first N02e66c6274f44e24a1c36a8b6fefdcaa
164 rdf:rest N83d610a1e38e435aa3b6f8f63b2a4c63
165 N9439207d7b394cc08b4b3a7df588b097 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Policy Making
167 rdf:type schema:DefinedTerm
168 N9e71587a231d4496bc9b8102b29b6464 schema:issueNumber 9
169 rdf:type schema:PublicationIssue
170 Naf6e6c4232c743ccb84927589f43fc6a rdf:first sg:person.016420255222.13
171 rdf:rest Nc90d807e21204259b92ec708e679a4a6
172 Nb99cf922424c49c3a2ee17ab1d16fb16 schema:name dimensions_id
173 schema:value pub.1130093751
174 rdf:type schema:PropertyValue
175 Nc90d807e21204259b92ec708e679a4a6 rdf:first sg:person.01327533357.46
176 rdf:rest N155f00c5e379444494dbf45e8a4d3c00
177 Ndb1115ec3df540d488438ee684dc0911 rdf:first sg:person.01331377620.80
178 rdf:rest Nec1a87cd24964af793341e440dec9877
179 Ne5b5e63ea41748c1bf8c842abdf76cad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Humans
181 rdf:type schema:DefinedTerm
182 Ne8e0ef068dea425c99551a8b5283979e rdf:first sg:person.014332745303.05
183 rdf:rest N6e6976b1fc524530878d1441f15a08f3
184 Nec1a87cd24964af793341e440dec9877 rdf:first sg:person.01331127566.82
185 rdf:rest Nef9fa38f0570495caf9098b956bd65c1
186 Ned39f0b672694d30a9b4d4611ec580f2 rdf:first sg:person.01002053374.17
187 rdf:rest Ndb1115ec3df540d488438ee684dc0911
188 Nef9fa38f0570495caf9098b956bd65c1 rdf:first sg:person.0752636034.37
189 rdf:rest Ne8e0ef068dea425c99551a8b5283979e
190 Nf4990d67612f4e3aa22a0e4cacb866c3 schema:name pubmed_id
191 schema:value 32794011
192 rdf:type schema:PropertyValue
193 Nf8137b66c55d421a8769de6136bbc80b schema:volumeNumber 21
194 rdf:type schema:PublicationVolume
195 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
196 schema:name Medical and Health Sciences
197 rdf:type schema:DefinedTerm
198 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
199 schema:name Public Health and Health Services
200 rdf:type schema:DefinedTerm
201 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
202 schema:name Economics
203 rdf:type schema:DefinedTerm
204 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
205 schema:name Applied Economics
206 rdf:type schema:DefinedTerm
207 sg:journal.1297512 schema:issn 1439-3972
208 1439-6637
209 schema:name The European Journal of Health Economics
210 schema:publisher Springer Nature
211 rdf:type schema:Periodical
212 sg:person.01002053374.17 schema:affiliation grid-institutes:grid.34477.33
213 schema:familyName Garrison
214 schema:givenName Louis
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002053374.17
216 rdf:type schema:Person
217 sg:person.011116672503.34 schema:affiliation grid-institutes:None
218 schema:familyName Ratcliffe
219 schema:givenName Mark
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011116672503.34
221 rdf:type schema:Person
222 sg:person.01172341334.33 schema:affiliation grid-institutes:None
223 schema:familyName Shah
224 schema:givenName Koonal
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172341334.33
226 rdf:type schema:Person
227 sg:person.012711633277.14 schema:affiliation grid-institutes:grid.5685.e
228 schema:familyName Palmer
229 schema:givenName Stephen
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012711633277.14
231 rdf:type schema:Person
232 sg:person.01322615152.98 schema:affiliation grid-institutes:grid.433167.4
233 schema:familyName Zhao
234 schema:givenName Kun
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322615152.98
236 rdf:type schema:Person
237 sg:person.01327533357.46 schema:affiliation grid-institutes:grid.466400.0
238 schema:familyName Durand-Zaleski
239 schema:givenName Isabelle
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46
241 rdf:type schema:Person
242 sg:person.01331127566.82 schema:affiliation grid-institutes:grid.7491.b
243 schema:familyName Greiner
244 schema:givenName Wolfgang
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331127566.82
246 rdf:type schema:Person
247 sg:person.01331377620.80 schema:affiliation grid-institutes:None
248 schema:familyName Graf von der Schulenburg
249 schema:givenName Johann-Matthias
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331377620.80
251 rdf:type schema:Person
252 sg:person.013455465123.21 schema:affiliation grid-institutes:None
253 schema:familyName Moutié
254 schema:givenName Anne-Sophie
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013455465123.21
256 rdf:type schema:Person
257 sg:person.014332745303.05 schema:affiliation grid-institutes:None
258 schema:familyName Meunier
259 schema:givenName Aurélie
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014332745303.05
261 rdf:type schema:Person
262 sg:person.015236747123.69 schema:affiliation grid-institutes:None
263 schema:familyName Farrington
264 schema:givenName Jasmine
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015236747123.69
266 rdf:type schema:Person
267 sg:person.016420255222.13 schema:affiliation grid-institutes:grid.28046.38
268 schema:familyName Coyle
269 schema:givenName Doug
270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016420255222.13
271 rdf:type schema:Person
272 sg:person.07353705215.15 schema:affiliation grid-institutes:None
273 schema:familyName Pemberton-Whiteley
274 schema:givenName Zack
275 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07353705215.15
276 rdf:type schema:Person
277 sg:person.0752636034.37 schema:affiliation grid-institutes:grid.7491.b
278 schema:familyName Longworth
279 schema:givenName Louise
280 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752636034.37
281 rdf:type schema:Person
282 sg:pub.10.1007/s10198-018-1007-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1107079490
283 https://doi.org/10.1007/s10198-018-1007-x
284 rdf:type schema:CreativeWork
285 sg:pub.10.1186/s12955-019-1189-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1117679632
286 https://doi.org/10.1186/s12955-019-1189-7
287 rdf:type schema:CreativeWork
288 grid-institutes:None schema:alternateName Acute Leukemia Advocates Network (ALAN)-Chair, Bern, Switzerland
289 AveXis, Chicago, USA
290 Center for Health Economics Research, Hannover, Hannover, Germany
291 PHMR Ltd, London, UK
292 schema:name Acute Leukemia Advocates Network (ALAN)-Chair, Bern, Switzerland
293 AveXis, Chicago, USA
294 Center for Health Economics Research, Hannover, Hannover, Germany
295 PHMR Ltd, London, UK
296 rdf:type schema:Organization
297 grid-institutes:grid.28046.38 schema:alternateName University of Ottawa, Ottawa, Canada
298 schema:name University of Ottawa, Ottawa, Canada
299 rdf:type schema:Organization
300 grid-institutes:grid.34477.33 schema:alternateName University of Washington, Seattle, USA
301 schema:name University of Washington, Seattle, USA
302 rdf:type schema:Organization
303 grid-institutes:grid.419481.1 schema:alternateName Novartis, Basel, Switzerland
304 schema:name Novartis, Basel, Switzerland
305 rdf:type schema:Organization
306 grid-institutes:grid.433167.4 schema:alternateName China National Health Development Research Center, Beijing, China
307 schema:name China National Health Development Research Center, Beijing, China
308 rdf:type schema:Organization
309 grid-institutes:grid.466400.0 schema:alternateName University of Paris Est, Champs-Sur-Marne, France
310 schema:name University of Paris Est, Champs-Sur-Marne, France
311 rdf:type schema:Organization
312 grid-institutes:grid.5685.e schema:alternateName Center for Health Economics, University of York, York, UK
313 schema:name Center for Health Economics, University of York, York, UK
314 rdf:type schema:Organization
315 grid-institutes:grid.7491.b schema:alternateName Bielefeld University, Bielefeld, Germany
316 schema:name Bielefeld University, Bielefeld, Germany
317 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...